This paper aims to review treatment delay in first-episode schizophrenia,depression,and bipolar disorder,and to compare related factors of treatment delay in the three first-episode mental disorders.It is found that increased patient responsibility,stigma,lack of disease-related knowledge,lack of access to resources,and insuffi-cient medical support lead to delay treatment,and making patients to have longer course,heavier symptoms,and lower social functions.

External Guide Sequences (EGSs) represents a novel nucleic acid based gene interference approach to modulate gene expression. They are oligonucleotides that consist of a sequence complementary to a target mRNA and recruit intracellular RNase P for specific degradation of the target RNA. DNA-based EGS1386 with a size of 12 nt was chemically synthesized to target the mRNA coding for the UL49 gene of human cytomegalovirus (HCMV). The DNA-based EGS1386 molecule efficiently directed human RNase P to cleave the target mRNA sequence in vitro. A reduction of more than 50% in the levels of UL49 expression was observed in human cells treated with the DNA-based EGS1386 targeted UL49 assayed by fluorescent quantization PCR and Western blotting. This results showed that the DNA-EGS1386 can effectively guide the RNase P cut the target mRNA. Therefore, DNA-EGS can develop into a new gene silencing technology and potential of the anti-viral reagents.
Base Sequence ; Cytomegalovirus ; drug effects ; genetics ; metabolism ; Cytomegalovirus Infections ; enzymology ; virology ; DNA, Viral ; genetics ; Directed Molecular Evolution ; methods ; Gene Expression Regulation, Viral ; Humans ; Nucleic Acid Conformation ; Oligodeoxyribonucleotides ; genetics ; pharmacology ; RNA, Guide ; chemistry ; pharmacology ; RNA, Messenger ; genetics ; metabolism ; Ribonuclease P ; genetics ; metabolism ; Viral Structural Proteins ; genetics ; metabolism

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairments with progressive loss of memory and behavioral disorder.Up to now,there is no effective therapy or drug to cure AD.Recent studies have shown p75 neurotrophin receptor (p75NTR) plays a critical role in the pathogenesis of AD,while the extracellular domain of p75 neurotrophin receptor (p75ECD) has neuroprotective effect and can attenuate the development and progression of AD.Therefore,p75ECD is a research-hotspot for prevention and treatment of AD.Here,recent studies are reviewed to learn about the advances of p75ECD in the prevention and therapy of AD and provide references for getting novel methods and drugs to treat AD.

Objective:To compare demographic characteristics,clinical characteristics,therapeutic characteris-tics and physiological indicators of patients with bipolar Ⅰ disorder and bipolar Ⅱ disorder.Methods:A total of 381 patients with bipolar disorder(BD)diagnosed by the Diagnostic and Statistical Manual of Mental Disorders 5 th Edi-tion(DSM-5)were selected,including 302 patients with BD-Ⅰ(79.27％),74 patients with BD-Ⅱ(19.42％)and 5 patients with other specific and related disorders(1.31％).Demographic and clinical characteristics were collected with self-designed clinical information questionnaire.Multivariate logistic regression and multivariate linear regres-sion analysis were used for analysis.Results:Compared with patients with BD-Ⅱ,patients with BD-Ⅰ had more risk to have psychotic features(OR=5.75,95％CI:2.82-11.76),longer disease duration,and more repeated transcra-nial magnetic therapy(OR=3.09,95％CI:1.02-9.35),higher uric acid,total cholesterol and high-density lipo-protein.BD-Ⅰ in Han nationality was more common(OR=11.50,95％CI:1.76-75.30),and had lower education level(OR=10.22,95％CI:1.16-89.77),and less family history of psychosis(OR=2.34,95％CI:1.01-5.42).Conclusion:There are significant differences between BD-Ⅰ and BD-Ⅱ in demographic and clinical charac-teristics,treatment status,and physiological indicators,which could provide clues for exploring the pathogenesis of bipolar disorder.